Trough colistin plasma level is an independent risk factor for nephrotoxicity: A prospective observational cohort study

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Sorlí, Luisa ^a   Luque, Sonia ^a   Grau, Santiago ^a   Berenguer, Núria ^a   Segura, Concepción ^c   Montero, María Milagro ^a   Álvarez Lerma, Francisco ^b   Knobel, Hernando ^a   Benito, Natividad ^d,e   Horcajada, Juan P ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b Pediatric Intensive Care Unit Service   (Spain)

^c Laboratorio de Referencia de Catalunya   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e NONE   (Spain)

Author keywords

Colistin; Colistin plasma levels; Nephrotoxicity risk factors; RIFLE criteria

Indexed keywords

AMINOGLYCOSIDE; AMINOGLYCOSIDE DERIVATIVE; AMPHOTERICIN B; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; COLISTIN; COLISTIN METHANESULFONATE SODIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYPERTENSIVE FACTOR; LOOP DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG INFUSION; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PREDICTION; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; RISK FACTOR; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COLISTIN; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SPAIN;

EID: 84882539817     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-380     Document Type: Article

References (31)

1. Falagas ME, Rafailidis PI, Kasiakou SK, Hatzopoulou P, Michalopoulos A. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant gram-negative bacterial infections. Clin Microbiol Infect 2006, 12:1227-1230. 10.1111/j.1469-0691.2006.01559.x, 17121631.
2. Montero M, Horcajada JP, Sorli L, Alvarez-Lerma F, Grau S, Riu M, et al. Effectiveness and safety of colistin for the treatment of multidrug-resistant pseudomonas aeruginosa infections. Infection 2009, 37:461-465. 10.1007/s15010-009-8342-x, 19499183.
3. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother 2003, 47:2659-2662. 10.1128/AAC.47.8.2659-2662.2003, 166058, 12878536.
4. Yahav D, Farbman L, Leibovici L, Paul M. Colistin: New lessons on an old antibiotic. Clin Microbiol Infect 2012, 18:18-29. 10.1111/j.1469-0691.2011.03734.x, 22168320.
5. Garnacho-Montero J, Amaya-Villar R. Multiresistant acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis 2010, 23:332-339. 10.1097/QCO.0b013e32833ae38b, 20581674.
6. Ko H, Jeon M, Choo E, Lee E, Kim T, Jun JB, et al. Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Nephron Clin Pract 2011, 117:c284-c288. 10.1159/000320746, 20847571.
7. Rattanaumpawan P, Ungprasert P, Thamlikitkul V. Risk factors for colistin-associated nephrotoxicity. J Infect 2011, 62:187-190. 10.1016/j.jinf.2010.11.013, 21129401.
8. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011, 53:879-884. 10.1093/cid/cir611, 21900484.
9. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009, 48:1724-1728. 10.1086/599225, 19438394.
10. Falagas ME, Fragoulis KN, Kasiakou SK, Sermaidis GJ, Michalopoulos A. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents 2005, 26:504-507. 10.1016/j.ijantimicag.2005.09.004, 16280245.
11. Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 2010, 54:4503-4505. 10.1128/AAC.01707-09, 2944569, 20660694.
12. Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE, et al. Colistin therapy for microbiologically documented multidrug-resistant gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010, 35:194-199. 10.1016/j.ijantimicag.2009.10.005, 20006471.
13. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39(2 Suppl 1):1-266. National Kidney Foundation.
14. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P,. Acute Dialysis Quality Initiative workgroup Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: The second international consensus conference of the acute dialysis quality initiative (ADQI) group. Crit Care 2004, 8:R204-R212. 10.1186/cc2872, 522841, 15312219, Acute Dialysis Quality Initiative workgroup.
15. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994, 47:1245-1251. 10.1016/0895-4356(94)90129-5, 7722560.
16. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1995, 13:818-829.
17. American college of chest Physicians/Society of critical care medicine consensus conference Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20:864-874. 10.1097/00003246-199206000-00025, 1597042, American college of chest Physicians/Society of critical care medicine consensus conference.
18. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Johnson DW. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2001, 25:167-175.
19. Couet W, Gregoire N, Marchand S, Mimoz O. Colistin pharmacokinetics: the fog is lifting. Clin Microbiol Infect 2012, 18:30-39. 10.1111/j.1469-0691.2011.03667.x, 21988234.
20. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006, 10:R27. 10.1186/cc3995, 1550802, 16507149.
21. Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res 2006, 4:138-146. 10.3121/cmr.4.2.138, 1483888, 16809407.
22. Vicari G, Bauer SR, Neuner EA, Lam SW. Association between colistin dose and microbiologic aoutomes in patients with multidrug-resistant gram-negative bacteremia. Clin Infect Dis 2013, 56:398-404. 10.1093/cid/cis909, 23090926.
23. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011, 55:3284-3294. 10.1128/AAC.01733-10, 3122440, 21555763.
24. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009, 53:3430-3436. 10.1128/AAC.01361-08, 2715599, 19433570.
25. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005, 11:115-121. 10.1111/j.1469-0691.2004.01043.x, 15679485.
26. Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, et al. High-dose, extended-interval colistin administration in critically ill patients: Is this the right dosing strategy? A preliminary study. Clin Infect Dis 2012, 54:1720-1726. 10.1093/cid/cis286, 3357480, 22423120.
27. Falagas ME, Kasiakou SK, Kofteridis DP, Roditakis G, Samonis G. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. Eur J Clin Microbiol Infect Dis 2006, 25:596-9. 10.1007/s10096-006-0191-2, 16955249.
28. Falagas ME, Rizos M, Bliziotis IA, Rellos K, Kasiakou SK, Michalopoulos A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 2005, 10(5):1.
29. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008, 52:1330-1336. 10.1128/AAC.01602-07, 2292536, 18227177.
30. Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: a systematic review. Kidney Int 2008, 73:538-546. 10.1038/sj.ki.5002743, 18160961.
31. Markou N, Markantonis SL, Dimitrakis E, Panidis D, Boutzouka E, Karatzas S, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: A prospective, open-label, uncontrolled study. Clin Ther 2008, 30:143-151. 10.1016/j.clinthera.2008.01.015, 18343250.